David Paul Richman, M.D.
Distinguished Professor
To see if David Paul Richman is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).
Locations and Contact
UC Davis Midtown Ambulatory Care Center
Midtown Neurology Clinic
3160 Folsom Blvd
Sacramento, CA 95816
Phone: 916-734-3588
Philosophy of Care
Dr. Richmand approaches his practice with 3 main goals to be: evidence-based, collaborative, and straight-forward.
Clinical Interests
David P. Richman's professional interests include biochemistry and pharmacology of the nicotinic acetylcholine receptor and muscle-specific kinase (MuSK), diseases of neuromuscular transmission, myasthenia gravis, anti-MuSK myastemia, and Lambert-Eaton myasthenic syndrome, and the pathogenesis and control of autoimmune response in myasthenia gravis. Richman has coauthored an extensive list of publications and book chapters on neurological disease and related topics
Research/Academic Interests
Dr. Richman studies the biological mechanisms that underlie diseases of the neuromuscular junction with the goal of improving their treatment. He primarily develops animal models of the diseases and test new treatments in this setting. He also assists in clinical trials of these new treatments.
Division
Neurology
Center/Program Affiliation
Undergraduate School
A.B., Princeton University, Princeton NJ 1965
Medical School
M.D., Johns Hopkins University School of Medicine, Baltimore MD 1969
Internship
Internal Medicine, Albert Einstein College of Medicine, New York City NY 1969-1970
Residency
Internal Medicine, Albert Einstein College of Medicine, New York City NY 1970-1971
Residency
Neurology, Resident and Chief Resident, Massachusetts General Hospital, Boston MA 1971-1974
Fellowship
Neuroimmunology, Harvard Medical School, Boston MA 1974-1976
UC Davis Distinguished Professor, 2017
Conquer Award for Myasthenia Gravis Research, Myasthenia Gravis Foundation of Illinois, 2002
Muscular Dystrophy Association, Post-Doctoral Fellowship, 1975, 1976
Kermit Osserman Post-Doctoral Fellowship, Myasthenia Gravis Foundation, 1974, 1975
Henry Viets Student Fellowship, Myasthenia Gravis Foundation, 1968
Oh S, Mao X, Manfredo-Vieira S, Lee J, Patel D, Choi EJ, Alvarado A, Cottman-Thomas E, Maseda D, Tsao PY, Ellebrecht CT, Khella SL, Richman DP, O’Connor KC, Herzberg U, Binder GK, Milone MC, Basu S, Payne AS. Precision targeting of autoantigen-specific B-cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T-cells. Nature Biotechnol. 2023 Jan 19. doi:10.1038/s41587-022-01637-z. Online ahead of print.
Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, Gilhus NE, Illa I, Kuntz NL, Massey J, Melms A, Murai H, Nicolle M, Palace J, Richman D, Verschuuren J. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology. 2021 Jan 19;96(3):114-122. doi:10.1212/WNL.0000000000011124. Epub 2020 Nov 3. PMID:33144515.
Nowak RJ, Coffey CS, Goldstein JM, Dimachkie MM, Benatar M, Kissel JT, Wolfe GI, Burns TM, Freimer ML, Nations S, Granit V, Smith AG, Richman DP, Ciafaloni E, Al-Lozi MT, Sams LA, Quan D, Ubogu E, Pearson B, Sharma A, Yankey JW, Uribe L, Shy M, Amato AA, Conwit R, O'Connor KC, Hafler DA, Cudkowicz ME, Barohn RJ; NeuroNEXT NN103 BeatMG Study Team. Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study. Neurology. 2021 Dec 2;98(4):e376–89. doi:10.1212/WNL.0000000000013121. Epub ahead of print. PMID:34857535.
Borges LS, Richman DP. Muscle-Specific Kinase Myasthenia Gravis. Front Immunol. 2020 May 8;11:707. doi:10.3389/fimmu.2020.00707. PMID:32457737.
Lara MS, Afify A, Ellis MP, Phan CT, Richman DP, Riess JW. Immune Checkpoint Inhibitor-Induced Myasthenia Gravis in a Patient with Advanced NSCLC and Remote History of Thymoma. Clin Lung Cancer. 2019 Jul;20(4):e489-e491. doi:10.1016/j.cllc.2019.04.007. Epub 2019 Apr 19. PMID:31085042.
Sanders DB, Juel VC, Harati Y, Smith AG, Peltier AC, Marburger T, Lou JS, Pascuzzi RM, Richman DP, Xie T, Demmel V, Jacobus LR, Aleš KL, Jacobus DP; Dapper Study Team. 3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia. Muscle Nerve. 2018 Apr;57(4):561-568. doi:10.1002/mus.26052. Epub 2018 Feb 2. PMID:29280483.
Bissig D, Manjunath R, Traylor BR, Richman DP, Ng KL. Acute Stroke Despite Dabigatran Anticoagulation Treated with Idarucizumab and Intravenous Tissue Plasminogen Activator. J Stroke Cerebrovasc Dis. 2017 Jun;26(6):e102-e104. doi:10.1016/j.jstrokecerebrovasdis.2016.12.037. Epub 2017 Apr 14. PMID:28416406.
Richman DP. Lrp4 antibodies in myasthenia gravis: Pathogenic or protective. European J Neurol. 2016;23(11):1593-1594. PMID:27753233.
Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, Kuntz N, Massey JM, Melms A, Murai H, Nicolle M, Palace J, Richman DP, Verschuuren J, Narayanaswami P. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology. 2016 Jul 26;87(4):419-25. doi:10.1212/WNL.0000000000002790. Epub 2016 Jun 29. PMID:27358333.
Oskarsson B, Rocke DM, Dengel K, Richman DP. Myasthenia gravis exacerbation after discontinuing mycophenolate: A single-center cohort study. Neurology. 2016 Mar 22;86(12):1159-63. doi:10.1212/WNL.0000000000002405. Epub 2016 Feb 5. PMID:26850977.